CytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on Thursday

CytomX Therapeutics (NASDAQ:CTMX) will likely be announcing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.11) per share and revenue of $12.3880 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.04. CytomX Therapeutics had a negative return on equity of 36.61% and a negative net margin of 166.40%.The firm had revenue of $10.26 million for the quarter, compared to analyst estimates of $4.68 million. On average, analysts expect CytomX Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

CytomX Therapeutics Stock Performance

CTMX opened at $3.32 on Wednesday. CytomX Therapeutics has a fifty-two week low of $1.72 and a fifty-two week high of $8.21. The company has a market capitalization of $565.03 million, a P/E ratio of -8.10 and a beta of 2.12. The stock has a fifty day moving average of $3.37 and a 200-day moving average of $4.30.

Analyst Ratings Changes

Several equities analysts recently commented on CTMX shares. Wolfe Research started coverage on shares of CytomX Therapeutics in a research note on Tuesday, May 19th. They issued an “outperform” rating and a $6.00 price target on the stock. Wall Street Zen raised shares of CytomX Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. HC Wainwright reduced their price objective on shares of CytomX Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Zacks Research raised shares of CytomX Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of CytomX Therapeutics in a research note on Tuesday, June 16th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, CytomX Therapeutics currently has an average rating of “Buy” and an average price target of $12.10.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN boosted its stake in shares of CytomX Therapeutics by 83.2% in the 4th quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 3,000 shares in the last quarter. Hsbc Holdings PLC acquired a new position in CytomX Therapeutics during the 4th quarter worth approximately $52,000. Bank of Nova Scotia acquired a new position in CytomX Therapeutics during the 4th quarter worth approximately $58,000. Invesco Ltd. bought a new position in CytomX Therapeutics in the 2nd quarter valued at approximately $32,000. Finally, Paces Ferry Wealth Advisors LLC bought a new position in CytomX Therapeutics in the 4th quarter valued at approximately $63,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.